SPP1 as a risk factor for patients with acute on chronic liver failure undergoing liver transplantation
International Immunopharmacology · 2023-07 · 120 · 110355
DOI: 10.1016/j.intimp.2023.110355 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023-07. Verfasst von Yeping Yu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; Central Laboratory, Department of Li…. Hauptthemen laut MEDLINE: Acute-On-Chronic Liver Failure, Liver Transplantation, End Stage Liver Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shanghai Jiao Tong University, School of Medicine, Shanghai Jiao Tong University, Program of Shanghai Academic Research Leader.
Abstract (Originalsprache)
BACKGROUND: Acute on chronic liver failure (ACLF) is characterized by systemic inflammation and significant mortality, calling for accurate assessment due to the diverse prognosis of liver transplantation (LT). METHODS: 8 patients with ACLF and 4 normal controls (NC) underwent peripheral blood mononuclear cells (PBMCs) transcriptomics, whereas 9 patients with ACLF and 3 NC had hepatic CD45+ T cells transcriptomics. Thecandidateindicatorfoundinthetranscriptomicswas confirmedbya retrospective cohort (n = 137) and one prospective cohort (n = 68). RESULTS: Transcriptomics revealed significant differentially expression genes (DEGs) and bioprocesses related to the PBMCs and hepatic CD45+ T cells. Secreted phosphoprotein 1 (SPP1) was identified as a potential indicator for ACLF patients receiving LT, which was supported by evidence from the cross-sectional cohorts. As the condition of ACLF got worse, so did SPP1 levels, which were associated with liver failure and coagulation failure. SPP1 levels prior to LT were considerably greater in non-survivors of ACLF within 90 days than that in survivors. In the derivation cohort and validation cohort, ACLF patients with elevated SPP1 levels had significantly shorter cumulative survival durations than those with low SPP1 levels, P = 0.02 and P < 0.001, respectively. The SPP1-MELD and SPP1-chronic liver failure consortium (CLIF-C) ACLF scores had comparatively larger areas under the receiver operating characteristic curves (AUCs) than MELD (P = 0.0388) and CLIF-C ACLF (P = 0.045). CONCLUSIONS: The circulating SPP1 showed promise as a predictor for ACLF patients receiving LT, which demonstrated the need for tracking the clinical outcome of LT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; Central Laboratory, Department of Liver Diseases, ShuGuang Hospital Affiliated to Shanghai University of C…
- Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Clinical Research Center, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Central Laboratory, Department of Liver Diseases, ShuGuang Hospital Affiliated to Shanghai University of Chinese Traditional Medicine, Shanghai, China.
- Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Electronic address: hanghualian@shsmu.edu.cn.
Förderung
- Shanghai Jiao Tong University
- School of Medicine, Shanghai Jiao Tong University
- Program of Shanghai Academic Research Leader
- National Natural Science Foundation of China
- Foundation for Innovative Research Groups of the National Natural Science Foundation of China
- Shanghai Institutes of Nutrition and Health CAS
- Shanghai Municipal Education Commission
- Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital
Zitieren
APA
Yu, Y., Mao, X., Wang, J., Chen, M., Wang, F., Kong, X., & Hang, H. (2023). SPP1 as a risk factor for patients with acute on chronic liver failure undergoing liver transplantation. International Immunopharmacology, 120, 110355. https://doi.org/10.1016/j.intimp.2023.110355
Vancouver
Yu Y, Mao X, Wang J, Chen M, Wang F, Kong X, et al. SPP1 as a risk factor for patients with acute on chronic liver failure undergoing liver transplantation. International Immunopharmacology. 2023;120:110355. doi:10.1016/j.intimp.2023.110355
BibTeX
@article{Yu2023,
author = {Yu, Yeping and Mao, Xinyi and Wang, Jieying and Chen, Mo and Wang, Fang and Kong, Xiaoni and Hang, Hualian},
title = {SPP1 as a risk factor for patients with acute on chronic liver failure undergoing liver transplantation},
journal = {International Immunopharmacology},
year = {2023},
volume = {120},
pages = {110355},
doi = {10.1016/j.intimp.2023.110355}
}
EUVIMED